ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Cambrex strikes again with acquisition of Avista

by Rick Mullin
November 22, 2018 | APPEARED IN VOLUME 96, ISSUE 47

Continuing a string of acquisitions, Cambrex has agreed to acquire Avista Pharma Solutions for $252 million. Avista is owned by Ampersand Capital Partners and operates three facilities in the U.S. and one in Scotland. It engages in a range of pharmaceutical services, including early-stage small-molecule development and testing as well as finished-dosage services. The deal follows Cambrex’s acquisition of Halo Pharma earlier this year, which added final-dosage services to Cambrex’s offerings.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment